Adicet Bio, Inc.

ACET Nasdaq SEC CIK 1720580
Follow Adicet Bio Weekly email: filings, results

Financials

Reported figures only · latest: Q3 2026 USD · US GAAP
Net income −$18.9M +29.7% vs same quarter last year
EPS, diluted −$1.76 +62.7% vs same quarter last year
Operating cash flow −$17.9M +19.7% vs same quarter last year
Operating income −$19.8M +29.2% vs same quarter last year
Net income by quarter
−$28.7M
−$28.2M
−$31.2M
−$26.9M
−$30.5M
−$20.2M
−$21.4M
−$18.9M
Q4 24 Q1 25 Q2 25 Q3 25 Q4 25 Q1 26 Q2 26 Q3 26

Source: SEC XBRL filings · latest filing

The long view

Fiscal years as reported · SEC XBRL filings, US GAAP
Revenue and net income10 fiscal years
−$150M−$100M−$50M$0FY17FY19FY21FY23FY25
Show the numbers
YearNet income
FY25−$116.8M
FY24−$117.1M
FY23−$142.7M
FY22−$69.8M
FY21−$62M
FY20−$36.7M
FY19−$28.1M
FY18−$9.3M
FY17−$33.8M
FY16-
Free cash flowOperating cash flow minus capital expenditure
−$100M−$75M−$50M−$25M$0FY17FY19FY21FY23FY25
Show the numbers
YearFree cash flow
FY25−$97M
FY24−$93.5M
FY23−$98.2M
FY22−$61.5M
FY21−$64.1M
FY20−$42.5M
FY19−$29M
FY18−$19.1M
FY17−$11M
FY16-